Work productivity loss in patients with tenosynovial giant cell tumors in the United States.

person Feng Lin Daiichi Sankyo, Basking Ridge, NJ info_outline Feng Lin, Jackie Kwong, Raluca Ionescu-Ittu, Irina Pivneva, Willy Wynant, Sherry Shi, Eric Q. Wu, John A. Abraham

Authors person Feng Lin Daiichi Sankyo, Basking Ridge, NJ info_outline Feng Lin, Jackie Kwong, Raluca Ionescu-Ittu, Irina Pivneva, Willy Wynant, Sherry Shi, Eric Q. Wu, John A. Abraham Organizations Daiichi Sankyo, Basking Ridge, NJ, Daiichi Sankyo, Inc., Basking Ridge, NJ, Analysis Group, Inc., Montreal, QC, Canada, Analysis Group, Inc., Montreal, QC, Analysis Group, Inc., Boston, MA, Thomas Jefferson University Hospital, Philadelphia, PA Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive and debilitating tumor that generally affects young working-age adults. This study assessed work productivity loss in TGCT patients. Methods: Incident patients aged 18-64 years with diagnosis of TGCT, who had earning and disability data, were identified in the OptumHealth database (Q1 1999 – Q1 2017). Patients were classified into surgical and non-surgical groups depending on the presence of joint surgery claim in postindex period. Control patients without TGCT were matched 10:1 with TGCT patients on age, gender, year of TGCT diagnosis, and follow-up duration. The number of days missed from work due to disability and medical visits post diagnosis was compared using Poisson regressions. General linear models were used to compare indirect costs associated with productivity loss. Results: A total of 1,395 TGCT patients (724 surgical; 671 non-surgical) were matched to 13,950 controls (36% female; mean age = 47 years). Both surgical and non-surgical TGCT patients had more comorbidities (mean Charlson Comorbidity Index (CCI): 0.3 vs 0.2; 0.4 vs 0.2; p < 0.001), had greater use of analgesic drugs (44% vs 20%; 40% vs 21%; p < 0.001) and MRI tests (47% vs 4%; 26% vs 3%; p < 0.001) in the 12 months before TGCT diagnosis compared with controls. Both surgical and non-surgical TGCT patients missed more time from work due to disability and medical visits and had higher indirect cost associated with productivity loss than matched controls. Disability burden was greater in patients receiving surgery. Conclusions: Regardless of receiving surgery or not, TGCT is associated with significant work productivity loss. These findings highlight the unmet need for effective treatments to reduce disability and restore function in TGCT patients. Surgical Non-surgical TGCT Matched control P-value TGCT Matched control P-value N 724 7,240 671 6,710 Patients with disability claim, % 17.8% 5.5% p < 0.001 12.2% 5.7% p < 0.001 Annual days of work missed, mean (SD) Due to disability 10 (37) 2 (18) 9 (42) 2 (19) Due to medical visits 11 (9) 4 (5) 9 (8) 4 (5) Indirect cost ($) per person-year*, mean (SD) 5,119 (6,916) 1,831 (3,873) 4,403 (7,793) 1,953 (9,122) * Additional statistical adjustment for CCI